Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Covaxin: Doomed to the dugout or ready to join the field of vaccine options?

Tayson DeLengocky, DO
Meds
January 7, 2022
103 Shares
Share
Tweet
Share

With apologies to the late Yankees slugger Yogi Berra, for pandemic-weary Americans, it’s like “déjà vu all over again,” as new lockdowns and mandatory mask mandates are being imposed across the globe.

The latest threat, the Omicron COVID-19 variant, has been a major source of breakthrough infections, including among those who have been fully vaccinated and boosted, such as United States Senators Elizabeth Warren and Cory Booker.

Pfizer, Moderna, Johnson & Johnson, and other U.S.-based vaccine manufacturers deserve a great deal of credit for proceeding with a sense of urgency in the early days of the pandemic.

In less than a year, they turned a COVID-19 vaccine from a vague hope into a market-ready solution to address an unprecedented public health crisis.

One class of vaccines might not be the best answer to all phases of the pandemic, though. When asked about a way forward, Pfizer CEO Albert Bourla on December 8 indicated that a fourth dose of the booster is only a matter of time.

As a clinician who has received two Pfizer doses and a booster without any side effects, I wholeheartedly embrace vaccination as a solution to this pressing public health crisis.

The question, though, is whether public health authorities should remain committed to only one category of vaccine or whether a broader response involving other categories of vaccines would be advisable.

The vaccines that Americans have come to love — or hate, depending all too often on their political persuasion, their understanding of the available data and personal biases — are based on mRNA technology.

From a scientific perspective, re-administering (or reloading) a vaccine, which would stimulate the production of the same spike-style antibodies to mitigate the infection, is only a temporary “band-aid” approach. Further, the long-term consequences of overloading mRNA vaccines are still unknown.

Inactivated vaccines, used for such conditions as seasonal influenza, polio, pertussis, rabies, and Japanese encephalitis, represent the other major category of vaccines.

Although Pfizer, Moderna, and Johnson & Johnson have become household names in the COVID-19 vaccine space, the public and the medical community should be aware of an efficacious vaccine, Covaxin (BBV152), which uses the well-established and time-tested inactivated vaccine approach.

Over the past 12 months, more than 128 million doses of Covaxin have been administered outside of the United States without any severe adverse side effects.

After long scrutiny by the World Health Organization (WHO), Covaxin was finally granted approval for an Emergency Use Listing in November 2021.

According to a study in The Lancet, a peer-reviewed medical journal, Covaxin is 93% effective in preventing severe Covid, and its effectiveness in preventing symptomatic Covid (77%) and asymptomatic Covid (63%) is impressive, as well.

Most importantly, Phase III clinical trials have shown vaccine efficacy of 71% against all variant-related COVID-19 disease.

Covaxin offered 90% efficacy against Kappa and 65.2% against Delta. It also elicits robust immune memory to COVID-19 and variants for at least six months, which suggests that it will have a strong immune response to the Omicron variant.

Unfortunately, Covaxin has hit a roadblock in the form of the Food and Drug Administration (FDA) ‘s refusal to grant permission for a Phase III clinical trial in the United States. In June 2021, the FDA turned down an Emergency Use Authorization for Covaxin submitted by Ocugen on behalf of the manufacturer Bharat Biotech.

Instead, the FDA recommended that Bharat Biotech/Ocugen seek approval for a Biologics License Application, which would take years to make its way through the approval process.

Could the very companies that helped so significantly in the early stages of the pandemic by quickly bringing vaccines to market now be exercising their influence in Washington to ensure that they remain the dominant players in the COVID-19 space, even if such dominance comes at the expense of public health?

It’s an uncomfortable question to ask, and perhaps for that reason, very few media outlets or public officials have raised it. Gratitude has its place, but it is not unreasonable for the American people to ask the U.S. pharmaceutical industry, “What have you done for me lately?”

Congress should explore whether the phenomenon of “regulatory capture” — which involves an industry exercising undue influence over the activities of the agency that sets the “rules of the game” for the industry’s operations — is standing in the way of what appears to be a safe, effective vaccine to combat COVID-19.

Whether in the defense industry, medical device industry or pharmaceutical industry, the connections between the regulator and the regulated are often too collegial to truly protect the interests of taxpayers and patients.

Favoritism by regulators comes at the expense of the general welfare of the American people.

After one year of free access to vaccination, many Americans are still hesitant to get vaccinated for different reasons. The current mRNA vaccines do not give lifetime protection but rather provide temporary protection (from 3-6 months at the most) until another variant surfaces.

Results of a study regarding Covaxin’s effectiveness against the Omicron variant will be released in a couple of weeks. If the results are mediocre, the search for a better vaccine will no doubt continue. However, if the results show positive protection against the Omicron variant, the American people should have the ability to select the best option for their needs without undue interference from the FDA.

Former House Speaker Newt Gingrich once observed that Americans place a high value on merit, even if it leads to unequal outcomes. Not all football quarterbacks should be treated like Joe Montana, Gingrich observed, but everyone, he said, should have the opportunity to try out for the team.

The FDA should take his aphorism to heart and begin the tryout — the Phase III clinical trial — at the earliest possible opportunity. Will Covaxin make its way to the field, or is it doomed to the dugout in the United States? Merit, not politics or cronyism, should determine the outcome.

Pfizer’s Albert Bourla has rightly characterized the behavior of those who circulate COVID-19 vaccine misinformation as “criminal.” So, too, is short-circuiting the evaluation process of a potentially efficacious treatment that could appeal to a broader swath of Americans and, in turn, bring the pandemic’s terrible toll closer to its end.

Tayson DeLengocky is an ophthalmologist.

Image credit: Shutterstock.com

Prev

We must start looking for drowning colleagues

January 7, 2022 Kevin 6
…
Next

I can’t make you care. But you should.

January 7, 2022 Kevin 9
…

Tagged as: COVID

Post navigation

< Previous Post
We must start looking for drowning colleagues
Next Post >
I can’t make you care. But you should.

More by Tayson DeLengocky, DO

  • Why is the world’s first universal coronavirus vaccine not in the FDA’s toolbox?

    Tayson DeLengocky, DO
  • The American public deserves more COVID-19 vaccine options

    Tayson DeLengocky, DO
  • a desk with keyboard and ipad with the kevinmd logo

    Osteopathic medicine and the growth of D.O. graduates as physicians

    Tayson DeLengocky, DO

Related Posts

  • The basics of the MMR vaccine from a pediatrician

    Roy Benaroch, MD
  • No, the HPV vaccine isn’t optional

    Chad Hayes, MD
  • A view from Canada: Defending vaccine passports

    Bryan Thomas and Colleen M. Flood
  • Major medical groups back mandatory COVID vaccine for health care workers

    Molly Walker
  • Novavax may be able to provide equitable access to another vaccine alternative

    Vibhav Prabhakar, Tejas Sekhar, and Divya Srinivasan
  • People over profit: Pfizer and Moderna must share vaccine technology

    Amber Gipson-Fine, MPH

More in Meds

  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast
    • Overcoming Parkinson’s: a journey of laughter and resilience

      Cynthia Poire Mathews, FNP | Conditions
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • Maximize sleep efficiency with stimulus control

      Pedram Navab, DO | Conditions
    • The Iranian diaspora’s fight for liberty: Overcoming challenges in the largest women’s rights movement of our century

      Montreh Tavakkoli, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • How This Doctor Found Purpose After a Devastating Injury
  • House Lawmakers Squabble Over HHS Budget
  • Infant Formula Crisis Exposed FDA and Industry Failings, Lawmakers Say
  • Building Vaccine Trust Among the General Public
  • Is It Business as Usual for the Drug Industry?

Meeting Coverage

  • Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer
  • Cannabis Use Common in Post-Surgery Patients on Opioid Tapering
  • Less Abuse With Extended-Release Oxycodone, Poison Center Data Suggest
  • Novel Strategies Show Winning Potential in Ovarian Cancer
  • Children Do Well With Fewer Opiates After Surgery
  • Most Popular

  • Past Week

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast
    • Overcoming Parkinson’s: a journey of laughter and resilience

      Cynthia Poire Mathews, FNP | Conditions
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • Maximize sleep efficiency with stimulus control

      Pedram Navab, DO | Conditions
    • The Iranian diaspora’s fight for liberty: Overcoming challenges in the largest women’s rights movement of our century

      Montreh Tavakkoli, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Covaxin: Doomed to the dugout or ready to join the field of vaccine options?
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...